Drug intelligence / Profile preview

GC3111B

Development stage: Phase 2
Lead developer: GC Biopharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GC3111B is an investigational adult **tetanus, diphtheria, and acellular pertussis vaccine** being developed by GC Biopharma for active immunization against tetanus, diphtheria, and pertussis. It is intended as a domestically developed Tdap vaccine, with GC Biopharma reporting in-house development and production of vaccine antigens and finished product, including a proprietary pertussis-manufacturing process. A Phase I/II study in healthy adults evaluates its safety and immunogenicity versus Boostrix. ([gcbiopharma.com](https://www.gcbiopharma.com/kor/news_view.do?idx=3037))

Targets

TCR-GC3111B (T-cell receptor recognizing influenza peptide–MHC complexes derived from GC3111B antigens)BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on GC3111B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC3111B.

Explore the full profile